Bronchiolitis: Two French studies demonstrate the effectiveness of nirsevimab to protect infants

After a 2022–2023 season marked by a severe epidemic of bronchiolitis due to respiratory syncytial virus (RSV), in particular in terms of emergency department visits and hospital admissions, on September 15, 2023 the French Government launched a preventive immunization campaign, administering nirsevimab (Beyfortus), to protect infants and reduce the circulation of the virus.

Facebook Comments